- Investing.com
Analyst Outlook | JMP Securities maintains a Market Outperform rating with a $7 price target, while other analysts adopt a cautious stance amid early-stage developments |
Market Potential | Explore RLYB116's target indications, representing a $5B market opportunity in rare diseases with limited competition and high unmet needs |
Financial Fortitude | With $46M cash runway into mid-2027, Rallybio demonstrates fiscal discipline amid pipeline transitions, boasting a strong current ratio of 9.98x |
Pipeline Pivot | Rallybio shifts focus to RLYB116, a C5 inhibitor, after discontinuing its lead FNAIT program, reshaping its development strategy and market position |
Metrics to compare | RLYB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRLYBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −11.3x | −3.7x | −0.4x | |
PEG Ratio | −0.13 | 0.38 | 0.00 | |
Price / Book | 1.8x | −2.9x | 2.6x | |
Price / LTM Sales | 103.2x | 68.3x | 3.0x | |
Upside (Analyst Target) | −52.1% | 291.8% | 54.6% | |
Fair Value Upside | Unlock | 4.1% | 9.7% | Unlock |
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.